In the present study, we investigated if MM patients receiving a single intravenous MV-NIS infusion had preexisting T-cell responses against ten different shared tumor antigens, and whether MV-NIS virotherapy enhanced their cytotoxic T-cell responses against these TAA. This evidence concerns the gene SLC5A5 and neoplasm.